Cargando…

Depo Medroxyprogesterone (DMPA) Promotes Papillomavirus Infections but Does Not Accelerate Disease Progression in the Anogenital Tract of a Mouse Model

Contraceptives such as Depo-medroxyprogesterone (DMPA) are used by an estimated 34 million women worldwide. DMPA has been associated with increased risk of several viral infections including Herpes simplex virus-2 (HSV-2) and Human immunodeficiency virus (HIV). In the current study, we used the mous...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Jiafen, Brendle, Sarah A., Li, Jingwei J., Walter, Vonn, Cladel, Nancy M., Cooper, Timothy, Shearer, Debra A., Balogh, Karla K., Christensen, Neil D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147738/ https://www.ncbi.nlm.nih.gov/pubmed/35632722 http://dx.doi.org/10.3390/v14050980

Ejemplares similares

Comparison of Sexual Dysfunction in Women Using Depo-Medroxyprogesterone Acetate (DMPA) and Cyclofem
por: Ozgoli, Giti, et al.
Publicado: (2015)

A Comparative Study on Delivery of Externally Attached DNA by Papillomavirus VLPs and Pseudoviruses
por: Brendle, Sarah, et al.
Publicado: (2021)

Is the Injectable Contraceptive Depo-Medroxyprogesterone Acetate (DMPA-IM) Associated with an Increased Risk for HIV Acquisition? The Jury Is Still Out
por: Hapgood, Janet P.
Publicado: (2020)

Mouse Papillomavirus L1 and L2 Are Dispensable for Viral Infection and Persistence at Both Cutaneous and Mucosal Tissues
por: Brendle, Sarah, et al.
Publicado: (2021)

Mouse papillomavirus infection persists in mucosal tissues of an immunocompetent mouse strain and progresses to cancer
por: Cladel, Nancy M., et al.
Publicado: (2017)

The Mouse Papillomavirus Infection Model
por: Hu, Jiafen, et al.
Publicado: (2017)

A Novel Pre-Clinical Murine Model to Study the Life Cycle and Progression of Cervical and Anal Papillomavirus Infections
por: Cladel, Nancy M., et al.
Publicado: (2015)

Papillomavirus can be transmitted through the blood and produce infections in blood recipients: Evidence from two animal models
por: Cladel, Nancy M., et al.
Publicado: (2019)

Depo-Provera (depot medroxyprogesterone acetate) use after bariatric surgery
por: Lam, Clarissa, et al.
Publicado: (2016)

Comparison of Two Different Injectable Contraceptive Methods: Depo-medroxy Progesterone Acetate (DMPA) and Cyclofem
por: Veisi, Firoozeh, et al.
Publicado: (2013)

CRPV Genomes with Synonymous Codon Optimizations in the CRPV E7 Gene Show Phenotypic Differences in Growth and Altered Immunity upon E7 Vaccination
por: Cladel, Nancy M., et al.
Publicado: (2008)

Uterine leiomyoma and its association with menstrual pattern and history of depo-medroxyprogesterone acetate injections
por: Amanti, L, et al.
Publicado: (2011)

Effects of Long-term Use of Depo-medroxyprogesterone Acetate on Lipid Metabolism in Nepalese Women
por: Yadav, Binod Kumar, et al.
Publicado: (2011)

An implementation project to expand access to self-administered depot medroxyprogesterone acetate (DMPA)()()
por: Katz, Micah, et al.
Publicado: (2020)

Clinical trial to evaluate pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate after subcutaneous administration of Depo-Provera
por: Halpern, Vera, et al.
Publicado: (2021)

Introduction of Community-Based Provision of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in Benin: Programmatic Results
por: Okegbe, Tishina, et al.
Publicado: (2019)

Oxidative Stress, Lipid Profile and Liver Functions in Average Egyptian Long Term Depo Medroxy Progesterone Acetate (DMPA) Users
por: Faddah, L. M., et al.
Publicado: (2005)

A comparative study on satisfaction from hormonal contraceptives: depot medroxyprogesterone acetate (DMPA), Cyclofem and LD
por: Fathizadeh, Nahid, et al.
Publicado: (2011)

Scaling up depot medroxyprogesterone acetate (DMPA): a systematic literature review illustrating the AIDED model
por: Curry, Leslie, et al.
Publicado: (2013)

Depot medroxyprogesterone acetate (DMPA) enhances susceptibility and increases the window of vulnerability to HIV-1 in humanized mice
por: Wessels, Jocelyn M., et al.
Publicado: (2021)

Trends in subcutaneous depot medroxyprogesterone acetate (DMPA-SC) use in Burkina Faso, the Democratic Republic of Congo and Uganda
por: Anglewicz, Philip, et al.
Publicado: (2019)

Modeling HPV-Associated Disease and Cancer Using the Cottontail Rabbit Papillomavirus
por: Cladel, Nancy M., et al.
Publicado: (2022)

Evaluating the feasibility and acceptability of self-injection of subcutaneous depot medroxyprogesterone acetate (DMPA) in Senegal: a prospective cohort study()()()
por: Cover, Jane, et al.
Publicado: (2017)

Characteristics associated with use of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) in Burkina Faso, Democratic Republic of Congo, and Uganda
por: Anglewicz, Philip, et al.
Publicado: (2021)

Health care provider and client experiences of counselling on depot medroxyprogesterone acetate subcutaneous (DMPA-SC) for self-injection in Malawi
por: Porter Erlank, Chelsey, et al.
Publicado: (2023)

The seahorse (Hippocampus comes L.) extract ameliorates sperm qualities, testosterone level, and serum biochemistry in rats induced by depo medroxyprogesterone acetate
por: Mundijo, Trisnawati, et al.
Publicado: (2023)

Expanding Access to Injectable Contraception: Results From Pilot Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in 4 African Countries
por: Stout, Anna, et al.
Publicado: (2018)

Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) Injectable Contraception at Facility and Community Levels: Pilot Results From 4 Districts of Uganda
por: Odwe, George, et al.
Publicado: (2018)

Anogenital-Associated Papillomaviruses in Animals: Focusing on Bos taurus Papillomaviruses
por: Yamashita-Kawanishi, Nanako, et al.
Publicado: (2020)

Factors Affecting Continued Use of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC): A Secondary Analysis of a 1-Year Randomized Trial in Malawi
por: Burke, Holly M., et al.
Publicado: (2019)

Cost-effectiveness of self-injected DMPA-SC compared with health-worker-injected DMPA-IM in Senegal()()
por: Mvundura, Mercy, et al.
Publicado: (2019)

Erratum for: Odwe et al., Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) Injectable Contraception at Facility and Community Levels: Pilot Results From 4 Districts of Uganda
Publicado: (2019)

Determinants of high-risk human papillomavirus infection in anogenital warts
por: Ozaydin-Yavuz, Goknur, et al.
Publicado: (2019)

Designing a global monitoring system for pilot introduction of a new contraceptive technology, subcutaneous DMPA (DMPA-SC)
por: Stout, Anna, et al.
Publicado: (2018)

Incidental Finding of Persistent Hydatidiform Mole in an Adolescent on Depo-Provera
por: Akinlaja, Olukayode, et al.
Publicado: (2016)

Diabetes insipidus in a patient with PCOS treated with Depo-Provera
por: Martinez, Amanda I, et al.
Publicado: (2022)

Viral metagenomics updated the prevalence of human papillomavirus types in anogenital warts
por: Xu, Hui, et al.
Publicado: (2019)

Wide Spectrum Analysis of Human Papillomavirus Genotypes in External Anogenital Warts
por: Rideg, Orsolya, et al.
Publicado: (2021)

Comparison of pregnancy incidence among African women in a randomized trial of intramuscular depot medroxyprogesterone acetate (DMPA-IM), a copper intrauterine device (IUDs) or a levonorgestrel (LNG) implant for contraception()()
por: Onono, Maricianah, et al.
Publicado: (2020)

Conjunctival Necrosis due to Subconjunctival Methylprednisolone (Depo-Medrol™) Acetate Injection
por: van Zyl, L. M., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_6vvotofhc1i3fa9i98p8jfdgd2